Pharvaris reports 83% drop in hereditary angioedema attacks in phase 3 trial, FDA decision pending

Pharvaris announced that its oral bradykinin B2 receptor antagonist, deucrictibant, met the primary goal in a second phase 3 study.

The trial, called CHAPTER-3, enrolled 85 patients with three forms of hereditary angioedema and tested a 40-mg once-daily extended-release formulation against placebo.

Results showed an 83% reduction in monthly attack rate versus placebo after 24 weeks, rising to 87% among the 80 patients with type 1 or type 2 HAE. All secondary endpoints, including attacks requiring on-demand medication, severe attacks, and symptom-free time, were also met.

Pharvaris filed an immediate-release version of deucrictibant with the FDA in July, with a decision expected by April 23 2027. If approved, the drug would provide an oral alternative to existing treatments such as KalVis.